Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 18/20 | 0.43 |
| ▸ | CPB1 | P15086 | 3/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839190 | 1.00 | CPB2 (0.43) | CPB2CPB1DUT | |
| SCHEMBL3840141 | 1.00 | CPB2 (0.43) | CPB2CPB1DUT | |
| SCHEMBL3841255 | 0.82 | CPB2 (0.64) | CPB2CPB1DUT | |
| SCHEMBL3841800 | 0.82 | CPB2 (0.57) | CPB2CPB1DUT | |
| SCHEMBL3839616 | 0.82 | CPB2 (0.57) | CPB2CPB1DUT | |
| SCHEMBL3841237 | 0.82 | CPB2 (0.57) | CPB2CPB1DUT | |
| SCHEMBL13617430 | 0.75 | CPB2 (0.46) | CPB2CPB1DUT | |
| SCHEMBL3637180 | 0.68 | CPB2 (0.36) | CPB2CPB1 | |
| SCHEMBL7758703 | 0.68 | MIF (0.42) | — | |
| SCHEMBL26693973 | 0.68 | DGAT1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CPB1 168/4885DUT 4385/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885DUT 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.